As previously reported, hyperactivation of the Wnt/β-catenin pathway is believed to be the initiating and driving event related to CRC and mechanistic findings highlighted that FXR exerted its tumor suppressor functions by antagonizing Wnt/β-catenin signaling. The gene discussed is NR1H4; the disease is neoplasm.